View source for Coronavirus treatments

== French study ==
French researchers using a small sample size found a high cure rate by using a combination of hydroxychloroquine and azithromycin (an antibiotic):<ref>Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of 
COVID‐19: results of an open‐label non‐randomized clinical trial. International Journal of 
Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949 [https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf]</ref>
{{Cquote|Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms.

Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.}}

An article in ''Nature'' also suggests the potential for off-label use of hydroxychloroquine, which was used long ago for [[malaria]] and was first synthesized in 1946, to treat [[coronavirus]] (SARS-CoV-2):<ref name="Nature">https://www.nature.com/articles/s41421-020-0156-0</ref>
{{cquote|[O]ur results show that HCQ [Hydroxychloroquine] can efficiently inhibit SARS-CoV-2 infection in vitro. In combination with its anti-inflammatory function, we predict that the drug has a good potential to combat the disease.}}
Communist China has been developing treatment guidelines, now in their sixth edition, faster than the [[United States]] has.  The Guidelines for the Diagnosis and Treatment of COVID-19 (6th Ed.), which is published by the National Health Commission of communist [[China]], lists chloroquine (CQ) phosphate as a potentially even better drug than HCQ due to a lower cost, more potent effect, and wider availability.<ref name="Nature"/>